Starpharma 1H losses grow on trial spending
Starpharma (ASX:SPL) widened its loss for the half-year ending in December, but still ended the period in a strong cash position of $39.3 million.
The company’s reported loss grew to $8.5 million, up from $5.6 million in the same period a year earlier.
Spending on the company’s clinical programs, including two phase III trials of antimicrobial gel VivaGel for the prevention of bacterial vaginosis, contributed to the wider loss.
The company is also involved in a phase I study of DEP-docetaxel, the dendrimer-enhanced formulation of the popular chemotherapeutic.
Starpharma’s cash balance of $39.3 million improved from $24 million at the start of the half-year period, thanks to the injection of $20.5 million in net proceeds from a placement and share purchase plan.
Another key milestone involved the first sales of the dual-branded Starpharma-Ansell VivaGel coated condom in Australia through Woolworths retail stores.
The companies also received regulatory approval in New Zealand, but fellow licensee Okamoto faced regulatory delays for its own VivaGel coated condom in Japan.
Starpharma meanwhile received a $4.2 million R&D tax incentive rebate during the period.
Starpharma (ASX:SPL) shares were trading 7.29% higher at $0.515 as of around 1 pm on Monday
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
